Are there any sideeffects to invermectin

Ivermectin has real side effects, but serious ones appear to be rare at standard doses. The evidence is thin on long-term harms and entirely missing on some key questions.

The largest and most recent meta-analysis, covering 40 randomized trials with over 23,000 participants, found no statistically significant difference in adverse event rates between ivermectin and placebo for COVID-19 treatment [3]. A separate 2025 meta-analysis of 23 trials (12,345 people) also found no significant increase in adverse events, with a pooled odds ratio of 0.87 [5]. These are the strongest signals we have: at standard doses, the drug does not cause a detectable spike in common side effects in these short-term studies.

But the picture is not blank. A 2018 pharmacovigilance study identified 28 cases of serious neurological adverse events after ivermectin use for non-onchocerciasis indications, including three with recurrence on rechallenge [1]. A 2022 analysis of the FDA's adverse event database found that ivermectin was associated with a significantly increased reporting of severe cutaneous reactions, with an adjusted odds ratio of 3.34 for any such reaction [4]. These are signals from passive reporting systems, which detect only a fraction of real events, but they point to rare but real risks: neurological symptoms and severe skin reactions.

The evidence is weakest on long-term safety. The trials are short, typically 21-28 days [2][3]. No study in this retrieval followed participants for months or years to look for delayed harms. The pregnancy safety data is very low certainty, with wide confidence intervals that cannot rule out a meaningful increase in miscarriage or birth defects [6]. The bottom line: for a short course at standard doses, the risk of a common side effect is low, but rare serious events do occur, and the absence of long-term data is a real gap.

My call: ivermectin's short-term side effect profile at standard doses is mild for most people, but rare serious neurological and skin reactions are documented, and the lack of long-term safety data means the full risk picture is unknown. Confidence: moderate for short-term safety, low for long-term safety.